Business Description
CNBX Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US13764M1009
Description
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.02 | |||||
| Equity-to-Asset | -80 | |||||
| Debt-to-Equity | -0.52 | |||||
| Debt-to-EBITDA | -2.15 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1291.53 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 80.2 | |||||
| 3-Year EPS without NRI Growth Rate | 81.2 | |||||
| 3-Year FCF Growth Rate | 84.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.25 | |||||
| 9-Day RSI | 40.52 | |||||
| 14-Day RSI | 42.8 | |||||
| 6-1 Month Momentum % | 27.5 | |||||
| 12-1 Month Momentum % | -15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.01 | |||||
| Quick Ratio | 0.01 | |||||
| Cash Ratio | 0.01 | |||||
| Days Payable | 10887.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -192.8 | |||||
| Shareholder Yield % | 104.71 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.62 | |||||
| Operating Margin % | -448.46 | |||||
| Net Margin % | -535.39 | |||||
| FCF Margin % | -188.46 | |||||
| ROA % | -299.74 | |||||
| ROIC % | -41.36 | |||||
| ROC (Joel Greenblatt) % | -245.75 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.5 | |||||
| EV-to-EBIT | -2.16 | |||||
| EV-to-EBITDA | -2.41 | |||||
| EV-to-Revenue | 11.19 | |||||
| EV-to-FCF | -5.94 | |||||
| Earnings Yield (Greenblatt) % | -46.3 | |||||
| FCF Yield % | -131.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CNBX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CNBX Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.13 | ||
| EPS (TTM) ($) | -0.015 | ||
| Beta | 0.11 | ||
| Volatility % | 81.94 | ||
| 14-Day RSI | 42.8 | ||
| 14-Day ATR ($) | 0.001807 | ||
| 20-Day SMA ($) | 0.00822 | ||
| 12-1 Month Momentum % | -15 | ||
| 52-Week Range ($) | 0.005 - 0.0199 | ||
| Shares Outstanding (Mil) | 31.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CNBX Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CNBX Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
CNBX Pharmaceuticals Inc Frequently Asked Questions
What is CNBX Pharmaceuticals Inc(CNBX)'s stock price today?
The current price of CNBX is $0.01. The 52 week high of CNBX is $0.02 and 52 week low is $0.01.
When is next earnings date of CNBX Pharmaceuticals Inc(CNBX)?
The next earnings date of CNBX Pharmaceuticals Inc(CNBX) is .
Does CNBX Pharmaceuticals Inc(CNBX) pay dividends? If so, how much?
CNBX Pharmaceuticals Inc(CNBX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers